Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
EEMT (esterified estrogens and methyltestosterone) 1.25 mg/2.5 mg Recalled by Syntho Pharmaceuticals, Inc. Due to CGMP deviations: Lots were recalled due to sub-potency...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Syntho Pharmaceuticals, Inc. directly.
Affected Products
EEMT (esterified estrogens and methyltestosterone) 1.25 mg/2.5 mg, tablets,100-count bottle, Rx only, Manufactured By: Syntho Pharmaceuticals, Inc., Farmingdale, NY 11735, Distributed By: Creekwood Pharmaceutical, Inc., Birmingham, AL 35242, NDC 15310-010-01
Quantity: 5,000 bottles
Why Was This Recalled?
CGMP deviations: Lots were recalled due to sub-potency and cGMP violations.
Where Was This Sold?
Product was sold to the firm's sole distributor who further distributed the product throughout the United States.
About Syntho Pharmaceuticals, Inc.
Syntho Pharmaceuticals, Inc. has 2 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report